TriSalus Life Sciences, Inc. Common Stock
$4.90
-$0.03 (-0.61%)
$4.86Day Range$5.05
Key Statistics
Market Cap
$303.56M
Shares Outstanding
61.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 11, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$5.03
Day High
$5.05
Day Low
$4.86
Volume
114.3K
VWAP
$4.93
Prev Close
$4.93
Transactions
--
Acc. Volume
--
About TriSalus Life Sciences, Inc. Common Stock
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSSIC 3841102 employees6272 WEST 91ST AVENUE, WESTMINSTER, CO, 80031415 336 8917IPO Aug 11, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001826667
- Composite FIGI
- BBG00Z1TKRG8
- Share Class FIGI
- BBG00Z1TKRH7
- Ticker Root
- TLSI
- SIC Code
- 3841
About TriSalus Life Sciences, Inc. Common Stock (TLSI) Stock
TriSalus Life Sciences, Inc. Common Stock (TLSI) closed the 2026-09-17 session at $4.90, down 0.61% versus the previous close (-0.03). The stock opened at $5.03 and traded between $4.86 and $5.05 during that session. Session trading volume was 114K shares. The volume-weighted average price (VWAP) is $4.93.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
TriSalus Life Sciences, Inc. Common Stock has a market capitalization of $303.6 million. The company operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry classification. TLSI is listed on the XNAS exchange. The company employs approximately 102 people. TriSalus Life Sciences, Inc. Common Stock is headquartered in WESTMINSTER, CO. The recorded listing date is 2023-08-11.
On this page you can find market TLSI stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector.